Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Cash & Current Investments: 2017-2024

Historic Cash & Current Investments for Protagonist Therapeutics (PTGX) over the last 8 years, with Dec 2024 value amounting to $418.9 million.

  • Protagonist Therapeutics' Cash & Current Investments rose 22.91% to $576.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year increase of 26.09%. This contributed to the annual value of $418.9 million for FY2024, which is 22.63% up from last year.
  • Protagonist Therapeutics' Cash & Current Investments amounted to $418.9 million in FY2024, which was up 22.63% from $341.6 million recorded in FY2023.
  • In the past 5 years, Protagonist Therapeutics' Cash & Current Investments ranged from a high of $418.9 million in FY2024 and a low of $237.4 million during FY2022.
  • In the last 3 years, Protagonist Therapeutics' Cash & Current Investments had a median value of $341.6 million in 2023 and averaged $332.6 million.
  • Per our database at Business Quant, Protagonist Therapeutics' Cash & Current Investments skyrocketed by 826.39% in 2020 and then decreased by 27.39% in 2022.
  • Over the past 5 years, Protagonist Therapeutics' Cash & Current Investments (Yearly) stood at $305.9 million in 2020, then grew by 6.88% to $326.9 million in 2021, then declined by 27.39% to $237.4 million in 2022, then surged by 43.93% to $341.6 million in 2023, then climbed by 22.63% to $418.9 million in 2024.